Skip to main content

Day: September 28, 2023

Response to Media Speculation

Written by Customer Service on . Posted in Public Companies.

SYDNEY, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Lithium Power International Limited (ASX: LPI) (“Lithium Power” or “the Company”) refers to recent media speculation regarding discussions between Corporación Nacional del Cobre de Chile (“Codelco”) and Lithium Power about a potential transaction. Lithium Power confirms that it is in discussions with Codelco regarding a potential transaction. However, at this stage, discussions between Lithium Power and Codelco are incomplete and no agreement on terms has been reached. Codelco has been granted due diligence and is continuing to undertake its due diligence investigations. Lithium Power notes that there is no certainty that the discussions with Codelco will lead to consummation of a transaction. Lithium Power will continue to keep the market fully informed, in accordance with its...

Continue reading

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

Written by Customer Service on . Posted in Public Companies.

BREXAFEMMECartonBREXAFEMMEBlister PackJERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance. This press release provides additional details on the voluntary product recall recently disclosed by SCYNEXIS. Risk Statement: The potential cross contamination with a non-antibacterial beta-lactam drug substance could lead to...

Continue reading

Update in relation to merger with Livent Corporation

Written by Customer Service on . Posted in Mergers And Acquisitions.

BRISBANE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Allkem Limited (ASX: AKE, “Allkem” or the “Company”) provides an update in relation to the proposed merger of equals between Allkem and Livent Corporation (“Livent”) announced to ASX on 10 May 2023 (“Transaction”). Transaction update Allkem is pleased to provide the following update on the progress of the Transaction:Further to Allkem’s announcement on 24 July 2023, Allkem Livent plc1 (“New TopCo”) has today filed with the U.S. Securities and Exchange Commission (“SEC”) Amendment No. 1 and Amendment No. 2 to the preliminary registration statement on Form S-4 that contains a proxy statement/prospectus (together the “Revised Preliminary Form S-4”) All competition and foreign investment approvals are expected to be received prior to the proposed closing of the Transaction Subject...

Continue reading

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

Written by Customer Service on . Posted in Public Companies.

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7th Annual Genetic Medicines Conference being held October 2-3, 2023 in NYC. Details regarding the fireside chat are as follows: Date: October 2, 2023 Location: Westin Grand Central, New York, NY Time: 1:30 p.m. ET Webcast Link: https://ir.ocugen.com/events/event-details/chardans-7th-annual-genetic-medicines-conference In...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.